Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
about
Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.Viewing protein fitness landscapes through a next-gen lens.Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitorsMeasuring the activity of protein variants on a large scale using deep mutational scanning.Deep mutational scanning: a new style of protein scienceDissecting enzyme function with microfluidic-based deep mutational scanningSaturation Mutagenesis of the HIV-1 Envelope CD4 Binding Loop Reveals Residues Controlling Distinct Trimer Conformations.BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived XenograftsQuantifying and understanding the fitness effects of protein mutations: Laboratory versus natureHigh-Throughput Assays to Assess the Functional Impact of Genetic Variants: A Road Towards Genomic-Driven Medicine.Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy.Multiplexed assays of variant effects contribute to a growing genotype-phenotype atlas
P2860
Q27853105-CE2E3442-0CBE-49AB-B078-12A8D9C211A6Q30367833-8279A8EB-168A-49CC-83E5-B3BBF3A2AD34Q33784436-32D6ABA5-425A-43FD-81DE-C16840D48D6DQ35234062-5500679E-2FE5-44BB-9AA2-7EEB888BF68BQ35541240-65667B73-A08C-4429-98E4-25410FE89A5EQ35740372-DF4FB8D3-5811-48C3-9374-7007EDC617B6Q36184440-0BB13DF6-4477-41DB-A06F-17C72908D9F9Q37056708-63A18A33-7F92-492C-B065-65E06BB8B59BQ38787151-4FFD03DC-4C71-4AB5-8211-0B703578019EQ39141707-86958051-AD59-4013-AF28-CD07D5FA38E5Q39173195-3FB826B9-A7E2-4BDF-B386-87661062664FQ48112768-E11E1F5C-5EF1-49F7-8947-FF42BF525572Q58802662-AA015A7C-10E0-4CCA-805F-358DA28E05CE
P2860
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
@ast
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
@en
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
@nl
type
label
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
@ast
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
@en
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
@nl
prefLabel
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
@ast
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
@en
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
@nl
P2093
P2860
P356
P1476
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
@en
P2093
Benjamin Roscoe
Michael R Green
Sung Mi Park
Timothy R Wagenaar
P2860
P304
P356
10.1111/PCMR.12171
P50
P577
2013-10-15T00:00:00Z